Cg Oncology, Inc.
Clinical trials sponsored by Cg Oncology, Inc., explained in plain language.
A biopharmaceutical company developing immunotherapies for bladder cancer.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Virus therapy shows promise for tough bladder cancer cases
Disease control OngoingThis phase 3 trial is testing a new treatment called cretostimogene grenadenorepvec for people with a type of bladder cancer (non-muscle invasive) that did not improve after standard BCG therapy. The treatment uses a modified virus to target and destroy cancer cells. About 190 pa…
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Bladder cancer breakthrough? virus therapy aims to stop recurrence
Disease control OngoingThis phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…
Phase: PHASE3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New Virus-Based therapy targets bladder cancer after BCG fails
Disease control TerminatedThis study tested a treatment called CG0070, a virus designed to attack cancer cells, in people with high-grade non-muscle invasive bladder cancer. Participants had already tried standard therapy (BCG) without success and chose not to have their bladder removed. The goal was to s…
Phase: PHASE2 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC